KR20240006509A - 항암제로서의 퓨린 유도체 - Google Patents

항암제로서의 퓨린 유도체 Download PDF

Info

Publication number
KR20240006509A
KR20240006509A KR1020237035424A KR20237035424A KR20240006509A KR 20240006509 A KR20240006509 A KR 20240006509A KR 1020237035424 A KR1020237035424 A KR 1020237035424A KR 20237035424 A KR20237035424 A KR 20237035424A KR 20240006509 A KR20240006509 A KR 20240006509A
Authority
KR
South Korea
Prior art keywords
alkyl
cancer
cycloalkyl
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237035424A
Other languages
English (en)
Korean (ko)
Inventor
스콧 스로너
다니엘 왼쏜
Original Assignee
탱고 테라퓨틱스, 인크.
메디비르 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 탱고 테라퓨틱스, 인크., 메디비르 아베 filed Critical 탱고 테라퓨틱스, 인크.
Publication of KR20240006509A publication Critical patent/KR20240006509A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237035424A 2021-03-17 2022-03-17 항암제로서의 퓨린 유도체 Pending KR20240006509A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162460P 2021-03-17 2021-03-17
US63/162,460 2021-03-17
PCT/US2022/020700 WO2022197892A1 (en) 2021-03-17 2022-03-17 Purine derivatives as anticancer agents

Publications (1)

Publication Number Publication Date
KR20240006509A true KR20240006509A (ko) 2024-01-15

Family

ID=81327909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237035424A Pending KR20240006509A (ko) 2021-03-17 2022-03-17 항암제로서의 퓨린 유도체

Country Status (11)

Country Link
US (1) US20240059689A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308566A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024511996A (cg-RX-API-DMAC7.html)
KR (1) KR20240006509A (cg-RX-API-DMAC7.html)
CN (1) CN117425656A (cg-RX-API-DMAC7.html)
AU (1) AU2022238886A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018799A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212292A1 (cg-RX-API-DMAC7.html)
IL (1) IL305991A (cg-RX-API-DMAC7.html)
MX (1) MX2023010909A (cg-RX-API-DMAC7.html)
WO (1) WO2022197892A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20240190A (es) * 2021-11-12 2024-09-13 Insilico Medicine Ip Ltd Inhibidores de moléculas pequeñas de la proteasa específica de ubiquitina 1 (usp1) y sus usos
KR20240117556A (ko) 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
EP4739397A1 (en) 2023-07-06 2026-05-13 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
CN117024253A (zh) * 2023-08-14 2023-11-10 江西阿尔法高科药业有限公司 一种药用级麝香草酚特定杂质的制备方法
AU2024378865A1 (en) 2023-11-10 2026-06-25 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025256544A1 (zh) * 2024-06-11 2025-12-18 福建盛迪医药有限公司 一种1-氨烷基修饰的呋喃核糖衍生物的制备方法
CN119751316A (zh) * 2024-12-20 2025-04-04 江南大学 一种1-苯基三氟甲基n-(氟磺酰基)氨基甲酸酯化合物的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2406129T3 (es) * 2007-10-05 2013-06-05 Verastem, Inc. Derivados de purina sustituidos con pirimidina
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
CN102127070A (zh) * 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
JP2011236198A (ja) * 2010-04-13 2011-11-24 Daiichi Sankyo Co Ltd モルホリノプリン誘導体
CN114702495A (zh) * 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
WO2020132269A1 (en) * 2018-12-20 2020-06-25 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors

Also Published As

Publication number Publication date
US20240059689A1 (en) 2024-02-22
BR112023018799A2 (pt) 2023-12-12
IL305991A (en) 2023-11-01
CN117425656A (zh) 2024-01-19
AU2022238886A1 (en) 2023-09-14
EP4308566A1 (en) 2024-01-24
CA3212292A1 (en) 2022-09-22
JP2024511996A (ja) 2024-03-18
MX2023010909A (es) 2024-02-13
WO2022197892A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US12304907B2 (en) Compounds and methods of use
US20240182481A1 (en) Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
US20240059689A1 (en) Purine derivatives as anticancer agents
US12403137B2 (en) Compounds and methods of use
CN107427521B (zh) 细胞周期蛋白依赖性激酶的抑制剂
US11986471B2 (en) Compounds and methods of use
EP4469445A1 (en) Compounds and methods of use
US20250171432A1 (en) Compounds and methods of use
WO2024233605A1 (en) Compounds and their use against cancer
EP4469438A1 (en) Compounds and methods of use
EP4469455A1 (en) Compounds and methods of use
WO2024233665A1 (en) Compounds and their use against cancer
JP2026506763A (ja) サイクリン依存性キナーゼ分解剤およびその使用方法
CA2902038C (en) Inhibitors of bruton's tyrosine kinase

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902